ViCentra Raises $85M to Scale Manufacturing and Accelerate Market Penetration of Kaleido Insulin Patch Pump
Led by new investor Innovation Industries, with matching contributions from existing investors, Partners in Equity and Invest-NL, the $85M round also drew support from EQT Life Sciences and Health Innovations, demonstrating strong confidence in ViCentra’s next phase of growth
Fresh capital fuels scale-up, regulatory pathway, and commercialization of Kaleido 2, the world’s smallest, lightest, and only lifestyle-oriented insulin patch pump in its class
Utrecht, the Netherlands — September 3, 2025
ViCentra, a European medical device company redefining insulin delivery for people with diabetes, today announced the successful close of an upsized $85 million Series D financing led by new investor Innovation Industries, a leading European deeptech venture capital firm, with matching participation from existing investors Partners in Equity and Invest-NL, alongside continued support from EQT Life Sciences and Health Innovations. With this fresh funding, ViCentra will accelerate manufacturing scale-up, launch the next-generation Kaleido 2 patch pump in Europe, and prepare for U.S. market entry.
